Skip to main content
Northwestern University Feinberg School of Medicine

Lurie Cancer Center and Northwestern Medicine Experts to Present at the 2025 AACR Annual Meeting

2025 AACR Annual Meeting header image

Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will share and discuss leading-edge research at the 2025 American Association for Cancer Research Annual Meeting,  April 25–30 in Chicago.  

The meeting theme, “Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact,” reflects the critical importance of advancing cancer research from the bench to the clinic and back to the bench.

Use #AACR25 to share insights from the meeting. Follow and tag:

@LurieCancer on X and @LurieCancer.bsky.social on Bluesky

@Northwestern Med on X

Some of our notable presentations and sessions are listed below. For a full list of presentations, visit the AACR website


Saturday, April 26

Bridging the Gap: Ensuring a Broad Representation of Patients in Cancer Clinical Trials
Dario Roque, MD – Invited Speaker

Somatic mosaicism as a driver of hematopoietic malignancies and inflammatory diseases
Lucy Godley, MD – Chair and Presenter

Chemistry to the Clinic Part 3 of 3: Advances in Ligand Discovery to Enable Previously Intractable Targets

Discovery of small molecule-mediated protein degradation pathways
Xiaoyu Zhang, PhD – Presenter

Sunday, April 27

Major Symposium- Mitochondrial Biology in Cancer
Navdeep Chandel, PhD -- Chair

Monday, April 28

Critical Dependencies in Hematologic Malignancies: A Hematologic Malignancies Working Group Town Hall
Lucy Godley, MD – Speaker

Tuesday, April 29

Clinical Trials Plenary Session – Biologics and T-cell Engagers

ICAM-1 directed chimeric antigen receptor (CAR) T cells (AIC100) in patients with advanced thyroid cancers: Clinical and translational data from the phase 1 dose escalation study
Jochen Lorch, MD, and Adam Lin, MD, PhD – Co-Authors

Phase II Clinical Trials

Phase II open-label multi-cohort study evaluating CPI-613 (devimistat) in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemo-refractory solid tumors
Carolyn Moloney, MD – Presenter

Wednesday, April 30

Late-Breaking Research: Clinical Research 4

Trop-2 expression and association with efficacy in patients treated with sacituzumab govitecan + pembrolizumab +/- carboplatin in the EVOKE-02 study of non-small cell lung cancer
Jyoti Patel, MD -- Presenter